ROIV · NASDAQ
Roivant Sciences (ROIV) Stock Price & Fundamentals
Roivant Sciences (ROIV) closed at $817.16 on Oct 9, 2026, up 0.44% from the previous close of $813.57.
Share price, past year
1Y +34.11%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $817.16 |
| Sep 30, 2026 | $828.56 |
| Aug 31, 2026 | $788.52 |
| Jul 31, 2026 | $811.40 |
| Jun 30, 2026 | $722.93 |
| May 29, 2026 | $738.73 |
| Apr 30, 2026 | $725.34 |
| Mar 31, 2026 | $722.29 |
| Feb 27, 2026 | $705.93 |
| Jan 30, 2026 | $672.62 |
| Dec 31, 2025 | $653.21 |
| Nov 28, 2025 | $683.42 |
| Oct 31, 2025 | $649.62 |
Key statistics
- Market cap
- $590.54B
- P/E (TTM)
- —
- EPS (TTM)
- −$0.47
- Revenue (TTM)
- $7.53M
- Net income (TTM)
- −$266.25M
- Shares outstanding
- 722.7M
- Dividend yield
- —
- 52-week range
- $609.30 – $838.14
Roivant Sciences's market cap is $590.54B, based on a share price of $817.16 and 722.7M shares outstanding as of Jun 30, 2026.
Financials
Roivant Sciences reported revenue of $8.26M for fiscal 2025, down 71.57% from fiscal 2024.
Roivant Sciences reported a net loss of $299.77M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Mar 31, 2026 | $8.26M | −71.6% | −$299.77M | −3,629.2% | −$0.54 | −$758.56M |
| FY2024ended Mar 31, 2025 | $29.05M | −11.2% | −$171.98M | −592.0% | −$0.24 | −$844.05M |
| FY2023ended Mar 31, 2024 | $32.71M | +3.8% | $4.35B | 13,294.2% | $5.23 | −$766.65M |
| FY2022ended Mar 31, 2023 | $31.53M | −43.0% | −$1.01B | −3,200.2% | −$1.42 | −$856.08M |
| FY2021ended Mar 31, 2022 | $55.29M | +132.3% | −$845.26M | −1,528.9% | −$1.26 | −$695.17M |
| FY2020ended Mar 31, 2021 | $23.80M | — | −$809.23M | −3,400.9% | −$1.28 | −$557.94M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q1 FY2026ended Jun 30, 2026 | $1.44M | −$189.84M | −$0.26 |
| Q4 FY2025ended Mar 31, 2026 | $2.52M | $302.99M | $0.34 |
| Q3 FY2025ended Dec 31, 2025 | $2.00M | −$265.89M | −$0.38 |
| Q2 FY2025ended Sep 30, 2025 | $1.57M | −$113.52M | −$0.17 |
| Q1 FY2025ended Jun 30, 2025 | $2.17M | −$223.36M | −$0.33 |
| Q4 FY2024ended Mar 31, 2025 | $7.57M | −$206.48M | −$0.28 |
| Q3 FY2024ended Dec 31, 2024 | $9.02M | $169.38M | $0.23 |
| Q2 FY2024ended Sep 30, 2024 | $4.48M | −$230.18M | −$0.31 |
Company profile
- Name
- Roivant Sciences Ltd.
- Ticker
- ROIV
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- 7th Floor, 50 Broadway, London, SW1H 0DB
- Incorporated in
- D0
- Fiscal year ends
- March
- SEC CIK
- 0001635088
Recent SEC filings
- Sep 18, 2026
- Sep 8, 2026
- Aug 28, 2026
- Aug 27, 2026
- Aug 6, 2026
- Aug 6, 2026
- May 20, 2026
- May 20, 2026
Frequently asked questions
What is Roivant Sciences's stock price?
Roivant Sciences (ROIV) closed at $817.16 on Oct 9, 2026, up 0.44% from the previous close of $813.57.
What is Roivant Sciences's market cap?
Roivant Sciences's market cap is $590.54B, based on a share price of $817.16 and 722.7M shares outstanding as of Jun 30, 2026.
How much revenue does Roivant Sciences make?
Roivant Sciences reported revenue of $8.26M for fiscal 2025, down 71.57% from fiscal 2024.
Does Roivant Sciences pay a dividend?
Roivant Sciences's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Roivant Sciences Ltd.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures